The tremendous success of GLP-1/GIP receptor agonists has ushered in a rapid paradigm shift in how we consider and treat chronic metabolic diseases, like obesity and associated comorbidities. These therapeutics have had far-reaching effects in improving quality of life. This has evolved how we think of chronic diseases, ushering in a new wave of innovation that targets the biology of aging, such as energy homeostasis and muscle regeneration to improve healthspan. How has our evolving knowledge of chronic diseases opened doors to better treatments? What are the next therapeutic targets on the horizon? What are the implications on access and on patients’ and payers’ behavior? Join this session for an engaging discussion on how this shifting therapeutic landscape has opened the door to next-generation drug development that tackles the root causes of chronic diseases.